STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-48)	BELUDAVIMAB
PRONUNCIATION	be" lue dav' i mab
THERAPEUTIC CLAIM	Treatment of SARS-CoV-2 infection

CHEMICAL NAMES

1. Immunoglobulin G1 [246-alanine,340-leucine,342-glutamic acid,438-leucine,444-serine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal VIR-7832 γ1-chain), disulfide with human monoclonal VIR-7832 κ-chain, dimer (Source: CAS)

2. Immunoglobulin G1-kappa, anti-[severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein, receptor binding domain (RBD)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-457) [VH (*Homo sapiens* IGHV1-18*01 (92.9%) -(IGHD) -IGHJ5*01 (92.9%), CDR-IMGT [8.8.20] (26-33.51-58.97-116)) (1-127) -*Homo sapiens* IGHG1*01, G1m17,1, G1v12 CH2 A1.1, L115, E117, G1v24 CH3 L107, S114 (CH1 K120 (224) (128-225), hinge 1-15 (226-240), CH2 G1.1>A (246), A115>L (340), I117>E (342) (241-350), CH3 D12 (366), L14 (368), M107>L (438), N114>S (444) (351-455), CHS (456-457)) (128-457)], (230-214')-disulfide with kappa light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-20*01 (93.7%) -IGKJ4*01 (100%), CDR-IMGT [7.3.8] (27-33.51-53.90-97)) (1'-107') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (236-236'':239-239'')-bisdisulfide, produced in a Chinese hamster ovary (CHO)-K1 cell line, glycoform alfa (Source: WHO pINN list 125)

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGASVKV	SCKASGYPFT	SYGISWVRQA	PGQGLEWMGW	50
ISTYQGNTNY	AQKFQGRVTM	TTDTSTTTGY	MELRRLRSDD	TAVYYCARDY	100
TRGAWFGESL	IGGFDNWGQG	TLVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	150
ALGCLVKDYF	PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	200
SSLGTQTYIC	NVNHKPSNTK	VDKKVEPKSC	DKTHTCPPCP	APELLAGPSV	250
FLFPPKPKDT	LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	300
PREEQYNSTY	RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPL	PEEKTISKAK	350
GQPREPQVYT	LPPSRDELTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	400
YKTTPPVLDS	DGSFFLYSKL	TVDKSRWQQG	NVFSCSVLHE	ALHSHYTQKS	450
LSLSPGK					457

Light chain

EIVLTQSPGT	LSLSPGERAT	LSCRASQTVS	STSLAWYQQK	PGQAPRLLIY	50'
GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QHDTSLTFGG	100'
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges

22-96	22''-96''	23'-89'	23'''-89'''	134'-194'	134'''-194'''	154-210	154''-210''
214'-230	214'''-230''	236-236''	239-239''	271-331	271'-331''	377-435	377''-435''

Glycosylation sites (N)
307 307''

MOLECULAR FORMULA	$C_{6498}H_{10094}N_{1744}O_{2039}S_{40}$
MOLECULAR WEIGHT	146.55 kDa
TRADEMARK	None as yet
SPONSOR	GlaxoSmithKline Research & Development Ltd.
CODE DESIGNATIONS	VIR-7832
CAS REGISTRY NUMBER	2423016-74-2
UNII	FM2MK5954W
WHO NUMBER	11961

gbk